Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22421642 | 1.00 | MMP1 (0.38) | MMP1MMP9MMP14FFAR2POLB | |
| SCHEMBL29878045 | 1.00 | MMP1 (0.38) | MMP1MMP9MMP14FFAR2POLB | |
| SCHEMBL24337164 | 1.00 | MMP1 (0.38) | MMP1MMP9MMP14FFAR2POLB | |
| SCHEMBL19401641 | 0.91 | FFAR2 (0.36) | MMP1MMP9MMP14FFAR2 | |
| SCHEMBL13260893 | 0.91 | FFAR2 (0.36) | MMP1MMP9MMP14FFAR2 | |
| SCHEMBL14511336 | 0.91 | FFAR2 (0.36) | MMP1MMP9MMP14FFAR2 | |
| SCHEMBL17305511 | 0.84 | SMN1; SMN2 (0.42) | POLBSMN1; SMN2 | |
| SCHEMBL19201191 | 0.84 | FFAR2 (0.32) | MMP1FFAR2 | |
| SCHEMBL19201193 | 0.84 | FFAR2 (0.32) | MMP1FFAR2 | |
| SCHEMBL26789813 | 0.84 | MMP1 (0.38) | MMP1MMP9MMP14FFAR2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216526-A1 | PREPARATION METHOD FOR DUAL-DRUG-LINKER OF ADC AND USE THEREOF | CHENGDU SCIMOUNT PHARMATECH CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| WO-2024052333-A1 | MULTIVALENT FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2024-03-14 | — | — | WO | disclosed |
| WO-2023144379-A1 | HIGH-AFFINITY LIGANDS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| WO-2021129678-A1 | CONJUGATE WITH RADIATION-RESPONSIVE GROUP AND USE THEREOF | 北京大学 | 2021-07-01 | — | — | WO | disclosed |
| EP-2898085-B1 | CELL LINES | MEDIMMUNE LTD (GB) | 2019-01-23 | — | — | EP | disclosed |
| EP-3327027-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | Pfizer Inc (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-3284751-A1 | ANTI-C-MET ANTIBODY AND ANTI-C-MET ANTIBODY-CYTOTOXIC DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF | Suzhou Suncadia Biopharmaceuticals Co., Ltd. (CN) | 2018-02-21 | — | — | EP | disclosed |
| US-9217015-B2 | Cyclosporin derivatives for the treatment and prevention of a viral infection | S&T GLOBAL INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20130303438-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. | 2013-11-14 | — | — | US | disclosed |
| WO-2013085925-A1 | ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS | IGENICA, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2012166560-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303438-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | HAVCR2, TSLP, ICOS | MMP1 3789/4885MMP9 4062/4885MMP14 2421/4885 |
| US-20240216526-A1 | PREPARATION METHOD FOR DUAL-DRUG-LINKER OF ADC AND USE THEREOF | SKP1, ADCY7, ERBB2 | MMP1 4315/4885MMP9 3233/4885MMP14 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.